A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd.
There is growing clinical interest in the use of 125I (half-life 59.4 days) and 103Pd (half-life 16.97 days) for permanent brachytherapy implants. These radionuclides pose interesting radiobiological challenges because, even with slowly growing tumours, significant tumour cell repopulation may occur during the long period taken to deliver the full radiation dose. This results in a considerable amount of the prescribed dose being wasted. There may also be changes in the tumour volume during treatment (due to oedema and/or shrinkage), thus altering the relative geometry of the implanted seeds and causing additional dose rate variations. This assessment examines the interaction between the above effects and additionally includes allowance for the influence of the relative biological effectiveness (RBE) of the radiations emitted by the two radionuclides. The results are presented in terms of the biologically effective doses (BEDs) and likely tumour control probabilities (TCPs) associated with the various parameter combinations. The overall BED enhancement due to the RBE effect is shown always to be greater than the RBE itself and is greatest in tumours which are radio-resistive and/or fast growing. The biological dose uncertainties are found to be less with 103Pd and the TCPs associated with this radionuclide are expected to be significantly higher in the treatment of some 'difficult' tumours. Using typically prescribed doses 125i appears to be better for treating radiosensitive tumours with long doubling times and which shrink fairly rapidly. However, unless 125I doses are reduced, this advantage may well be offset by the greatly enhanced biological doses delivered to adjacent normal structures.
Antipas
V
V
Department of Medical and Biological Systems, Imperial College of Science, Technology and Medicine, London, UK.
Dale
R G
RG
Coles
I P
IP
D000230:Adenocarcinoma / Q000532:radiotherapy; D001918:Brachytherapy / Q000379:methods*; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D009369:Neoplasms / Q000532:radiotherapy*; D018307:Neoplasms, Squamous Cell / Q000532:radiotherapy; D010165:Palladium / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000532:radiotherapy; D011868:Radioisotopes / Q000627:therapeutic use*; D011874:Radiometry / Q000379:methods*; D011878:Radiotherapy / Q000379:methods*
D007457:Iodine Radioisotopes; D011868:Radioisotopes; D010165:Palladium